发明授权
US09492542B2 Pharmaceutical composition for the treatment of MCP-1 mediated inflammatory diseases
有权
用于治疗MCP-1介导的炎性疾病的药物组合物
- 专利标题： Pharmaceutical composition for the treatment of MCP-1 mediated inflammatory diseases
- 专利标题（中）： 用于治疗MCP-1介导的炎性疾病的药物组合物
-
申请号： US13497175申请日： 2010-09-03
-
公开(公告)号： US09492542B2公开(公告)日： 2016-11-15
- 发明人: Angelo Guglielmotti , Beatrice Garrone , Alessandro Ble' , Giuseppe Biondi
- 申请人： Angelo Guglielmotti , Beatrice Garrone , Alessandro Ble' , Giuseppe Biondi , Roberta Petrosemolo , Enrica Biondi , Iacopo Biondi
- 申请人地址： IT Rome
- 专利权人： AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A.
- 当前专利权人： AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A.
- 当前专利权人地址： IT Rome
- 代理机构： Oblon, McClelland, Maier & Neustadt, L.L.P.
- 优先权： EP09425368 20090923
- 国际申请： PCT/EP2010/062979 WO 20100903
- 国际公布： WO2011/036047 WO 20110331
- 主分类号： A61K31/425
- IPC分类号： A61K31/425 ; A61K45/06 ; A61K31/165 ; A61K31/366 ; A61K31/40 ; A61K31/403 ; A61K31/415 ; A61K31/416 ; A61K31/4178
摘要：
The present invention relates to a pharmaceutical composition comprising a combination of 1-benzyl-3-hydroxymethylindazole derivative, a pressure lowering agent selected from ACE-inhibitors, renin inhibitors, ARBs and CCBs, and/or a cholesterol lowering agent selected from statin derivatives. The combination showed an additive and synergistic activity in reducing MCP-1 levels, thus significantly improving inflammatory response inhibition and consequently reducing complications occurring in patients suffering from inflammatory diseases.
公开/授权文献
信息查询
